New UCB chief starts and expands team
pharmafile | January 13, 2015 | News story | Sales and Marketing | Cimzia, Jean-Christophe Tellier, Neupro, UCB, roch deliveux, vimpat
New UCB chief executive Jean-Christophe Tellier who succeeded Roch Doliveux this year has also welcomed three new members to the Belgium biopharma firm.
As announced in 2014 Tellier, who is also its chairman, replaced Doliveux in the top job after he stepped down on 31 December after leading UCB for the last 10 years. Its board of directors granted Doliveux the titles of honorary member of the board and honorary chairman of the executive committee.
Tellier joined the company in 2011 and was instrumental in establishing the company’s current strategy and playing a key role in driving UCB’s three core offerings: Cimzia, Vimpat and Neupro.
With a 25-year career stint in the biopharma industry, UCB says Tellier arrives with significant expertise and a medical background as a rheumatologist with a passion for developing talent.
Tellier says: “UCB’s leadership team has done a tremendous job in transforming the company into a global science leader helping patients with severe diseases enjoy more normal lives. It is important for UCB to ensure leadership continuity while adding expertise in our focus areas of neurology and immunology to accelerate momentum as we head into our next period of growth.”
From February the firm’s executive committee team is adding three new additions with each unit being led by an executive VP, who will be reporting in to Tellier, and the teams are to be structured as follows:
Patient Value units:
New Medicines: Ismail Kola, New Medicines head and chief scientific officer
Neurology: Jeff Wren, Patient Value unit head, previously head of UCB’s North American region
Immunology: Emmanuel Caeymaex, Patient Value unit head, previously head of UCB’s Cimzia team
Bone disorders: this position is still to be filled and will be led ad interim by Iris Loew Friedrich
Patient Value practices:
Strategic Marketing : Bharat Tewarie, Chief Marketing officer. A doctor with strong industry experience, he joins UCB from Merck-Serono where he was senior VP, head of Global Business Franchise Neurology & Immunology and head of Global Business Franchise Medical Devices
Development and Medical: Iris Loew Friedrich, chief medical officer
Patient Value operations:
Geographic Operations, Established Brands, Technical Operations and Business Development: Mark McDade, chief operating officer
Patient Value functions:
Finance: Detlef Thielgen, chief financial officer
Talent and Company Reputation: Fabrice Enderlin, chief talent officer
Legal: Anna Richo, general counsel.
Related Content
FDA accepts UCB’s sBLA for Bimzelx
UCB has announced that the US Food and Drug Administration (FDA) has accepted for review …
Microsoft and UCB collaborate to treat immunological and neurological diseases
UCB and Microsoft have agreed a new multi-year collaboration to discover new medicines by combining …
EMA expands label for UCB’s Cimzia in axial spondyloarthritis
The European Medicines Agency has expanded the existing approval of UCB’s Cimzia (certolizumab pegol) to …
